San Diego-centered Viking Therapeutics marked by itself as a serious competitor in the weight loss drug current market in February after revealing promising information from the mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection and in March the compa